Daniel Guendel

Dr. Daniel Guendel

HZDR, Institute for Radiopharmaceutical Cancer Research, Research Site Leipzig
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
MAMareli Allmeroth
Mareli Allmeroth
DMDorothea Moderegger
Dorothea Moderegger
Daniel GuendelDaniel Guendel
Daniel Guendel
HBHans-Georg Buchholz
Hans-Georg Buchholz
NMNicole Mohr
Nicole Mohr
RZRudolf Zentel
Rudolf Zentel

1 January 2016
Verified
Book Chapter
Closed access
PDF file
ARA. Riemann
A. Riemann
BSB. Schneider
B. Schneider
Daniel GuendelDaniel Guendel
Daniel Guendel
CSC. Stock
C. Stock
MGM. Gekle
M. Gekle
OTO. Thews
O. Thews

16 February 2014 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
ARAnne Riemann
Anne Riemann
BSBettina Schneider
Bettina Schneider
Daniel GuendelDaniel Guendel
Daniel Guendel
CSChristian Stock
Christian Stock
OTOliver Thews
Oliver Thews
MGMichael Gekle
Michael Gekle

16 November 2015 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
LWLeona Wagner
Leona Wagner
RWRaik Wolf
Raik Wolf
UZUlrike Zeitschel
Ulrike Zeitschel
SRSteffen Rossner
Steffen Rossner
ÅPÅsa Petersén
Åsa Petersén
SHStephan von Hörsten
Stephan von Hörsten

26 August 2013 in Biomacromolecules
Verified
Journal Article
Closed access
MAMareli Allmeroth
Mareli Allmeroth
DMDorothea Moderegger
Dorothea Moderegger
Daniel GuendelDaniel Guendel
Daniel Guendel
KKKaloian Koynov
Kaloian Koynov
HBHans-Georg Buchholz
Hans-Georg Buchholz
OTOliver Thews
Oliver Thews

1 December 2019 in International Journal of Pharmaceutics: X
Verified
Journal Article
Open access
ELE. Lehner
E. Lehner
Daniel GuendelDaniel Guendel
Daniel Guendel
ALA. Liebau
A. Liebau
SPS. Plontke
S. Plontke
Karsten MäderKarsten Mäder
Karsten Mäder
The effective treatment of diseases of the inner ear is currently an unmet medical need. Local controlled drug delivery to the cochlea is challenging due to the hidden location, small volume and high sensitivity of this organ. A local intracochlear delivery of drugs would avoid the problems of intratympanic (extracochlear) drug application, but is more invasive. The requirements for such a delivery system include a small size and appropriate flexibility. The delivery device must be rigid enough for surgical handling but also flexible to avoid traumatizing cochlear structures. We developed biodegradable dexamethasone loaded PLGA extrudates for the controlled intracochlear release. In order to achieve the desired flexibility, Polyethylene glycol (PEG) was used as a plasticizer. In addition to the drug release, the extrudates were characterized in vitro by differential scanning calorimetry (DSC) and texture analysis. Simulation of the pharmacokinetics of the inner ear support the expectation that a constant perilymph drug level is obtained after few hours and retained over several weeks. Ex vivo implantation of the extrudates into a guinea pig cochlea indicate that PEG containing extrudates have the desired balance between mechanical strength and flexibility for direct implantation into the cochlea. The location of the implant was visualized by computer tomography. In summary, we postulate that intracochlear administration of drug releasing biodegradable implants is a new and promising approach to achieve local drug delivery to the cochlea for an extended time.